rejuvant life tabs

bioage - search results

HitGen and BioAge progress drug discovery collaboration

Companies announce research progress in DNA-encoded library-based drug discovery research collaboration. Shanghai Stock Exchange-listed biotech HitGen, Inc announced important research progress in a collaboration with BioAge Labs, Inc yesterday. BioAge...

BioAge’s Phase 2 trial to reverse immune aging

...longevity biotech company BioAge Labs today announced the initiation of another Phase 2 trial, this time targeting COVID-19. The study will evaluate the efficacy and safety of BGE-175 to treat...

BioAge kicks off Phase 2 longevity clinical trial

...last year, longevity biotech company BioAge Labs has announced the start of a Phase 2a clinical trial of its BGE-117 for unexplained anaemia of aging (UAA). The multi-centre, randomised, double-blind,...

A year in longevity: investment perspectives

...Longevity biotech firm BioAge Labs which is readying itself for clinical trials after raising a whopping $90 million Series C funding round. Also in December, Silicon Valley’s Rubedo Life Sciences...

A year in Longevity: founders’ perspectives

...will tell, but it’s thrilling to see so many great minds working towards what is ultimately a common goal: the extension of healthy human lifespan. Kristen Fortney, BioAge Labs After...

BioAge CEO: “It’s all about the data.”

...a time.” This singular focus on delivering results in humans is at the forefront of what BioAge is all about. BioAge’s proprietary platform analyzes a vast amount of data from...

Silicon Valley is waking up to Longevity and senolytics

Silicon Valley’s Rubedo Life Sciences closes $12m seed round for proprietary drug discovery platform that targets senolytics. Following-on from BioAge’s funding announcement, another biotech start-up has secured financing to progress...

BioAge lands $90 million; gears up for clinical trials in 2021

...the fund of genomics entrepreneur Mostafa Ronaghi, among others. BioAge scientists at work in the lab. Source: BioAge “BioAge is at the forefront of understanding scientific drivers of aging with...

Big pharma enters senolytic drug discovery programme

...drug development experience. Taisho has already dipped its toe in the Longevity pool; the HIF-PH inhibitor recently licensed by BioAge was also developed by them. “We’re delighted to collaborate with...

New immune aging drug brings Longevity and C19 hope

Phase 2-ready drug can treat and reverse immune aging, BioAge claims. BioAge Labs‘ in-licensed clinical-stage therapy has potential for treating immune aging in older patients hospitalised with COVID-19, tackling both...

Latest articles

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

New research institute focuses on science of aging

New Bakar Aging Research Institute aims to drive deeply collaborative research to enhance translational medicine, progressing novel therapies from lab to clinic to community. UC...

The Sheekey Science Show – Precision Medicine

What to expect for Precision medicine by 2030? All of us are unique. What may good for one persons health may be terrible for another's....
Rejuvant